Table 3.

SNPs in chr6p Associated With Abnormal Decline of LVEF in Patients Treated With DOX-Based Chemotherapy

SNP	Gene Symbol	Base Position	Minor Allele	Major Allele	Min	Maj	All	Abnormal LVEF	Normal LVEF	OR	p Value
rs9264942	HLA-C	31274380	G	A	0.6	0.15	4/10/16	4/10/16	0/6/14	8.61	0.01
rs2523619	HLA-C	31318144	G	A	0.55	0.15	4/9/17	4/9/17	0/6/14	6.56	0.01
rs10484554	HLA-C	31274555	A	G	0.35	0.07	2/6/22	2/6/22	0/3/17	5.41	0.04
rs2071591	NFKBIL1	31515799	A	G	0.6	0.25	5/12/13	5/12/13	1/8/11	6.83	0.02
rs3093949	NFKBIL1	31525184	A	G	0.6	0.22	5/11/14	5/11/14	1/7/12	8.87	0.01
rs2071592	NFKBIL1	31515340	A	T	0.6	0.22	5/11/14	5/11/14	1/7/12	7.99	0.01
rs2071594	ATP6V1G	31512720	C	G	0.6	0.25	5/12/13	5/12/13	1/8/11	6.83	0.02
rs3130059	ATP6V1G	31509284	G	C	0.6	0.25	5/12/13	5/12/13	1/8/11	6.83	0.02
rs11796	ATP6V1G	31501212	T	A	0.6	0.27	6/11/13	6/11/13	2/7/11	4.12	0.03
rs2050190	C6orf10	32339076	G	A	0.6	0.2	6/8/16	6/8/16	1/6/13	3.89	0.02
rs1800629	TNF-α	31543031	A	G	0.35	0.07	2/6/22	2/6/22	0/3/17	5.67	0.03
rs3131379	MSH5	31721033	A	G	0.2	0.05	0/6/24	0/6/24	0/2/18	11.58	0.04
rs3131378	MSH5	31725285	G	A	0.2	0.05	0/6/24	0/6/24	0/2/18	11.58	0.04
rs2523451	MICA	31369151	A	G	0.5	0.22	3/13/14	3/13/14	0/9/11	4.50	0.04
rs909253	LTA	31540313	G	A	0.6	0.25	5/12/13	5/12/13	1/8/11	6.83	0.02
rs1041981	LTA	31540784	A	C	0.6	0.25	5/12/13	5/12/13	1/8/11	6.83	0.02
rs2239527	BAT1	31509779	G	C	0.5	0.25	4/12/14	4/12/14	1/8/11	4.13	0.05
rs3134931	NOTCH4	32190620	G	A	0.2	0.45	3/16/11	3/16/11	3/12/5	0.22	0.05

Min, minor allele frequency; Maj, major allele frequency; All, distribution of genotypes among all subjects treated with Dox-based chemotherapy (genotypes are ordered as mm/Mm/MM, where “m” and “M” are the minor and major alleles, respectively); abnormal LVEF, distribution of genotypes among subjects who developed abnormal LVEF decline; normal LVEF, distribution of genotypes among subjects who maintained normal LVEF; OR, estimated odds ratio for development of DOX cardiotoxicity (for minor allele; major allele is a reference).